- Previous Close
82.40 - Open
82.14 - Bid 84.86 x 300
- Ask 85.03 x 400
- Day's Range
81.74 - 85.29 - 52 Week Range
40.01 - 177.37 - Volume
1,445,794 - Avg. Volume
1,365,739 - Market Cap (intraday)
2.852B - Beta (5Y Monthly) 1.99
- PE Ratio (TTM)
91.37 - EPS (TTM)
0.93 - Earnings Date Oct 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
139.25
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
www.transmedics.comRecent News: TMDX
View MorePerformance Overview: TMDX
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TMDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TMDX
View MoreValuation Measures
Market Cap
2.77B
Enterprise Value
2.95B
Trailing P/E
88.60
Forward P/E
51.55
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.10
Price/Book (mrq)
13.17
Enterprise Value/Revenue
7.36
Enterprise Value/EBITDA
45.59
Financial Highlights
Profitability and Income Statement
Profit Margin
8.14%
Return on Assets (ttm)
2.84%
Return on Equity (ttm)
19.41%
Revenue (ttm)
401.09M
Net Income Avi to Common (ttm)
32.64M
Diluted EPS (ttm)
0.93
Balance Sheet and Cash Flow
Total Cash (mrq)
330.09M
Total Debt/Equity (mrq)
246.83%
Levered Free Cash Flow (ttm)
-142.59M
Research Analysis: TMDX
View MoreCompany Insights: TMDX
TMDX does not have Company Insights
Research Reports: TMDX
View MoreRating increased to a HOLD
TRANSMEDICS GROUP INC has an Investment Rating of HOLD; a target price of $93.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $98.00
TRANSMEDICS GROUP INC has an Investment Rating of SELL; a target price of $98.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $105.00
TRANSMEDICS GROUP INC has an Investment Rating of SELL; a target price of $105.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRating decreased to a SELL
TRANSMEDICS GROUP INC has an Investment Rating of SELL; a target price of $110.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target